GASTROENTEROPATHIES ASSOCIATED WITH ACETYLSALICYLIC ACID: HOW TO IMPROVE SAFETY OF THERAPY

Abstract

Lesion of gastrointestinal mucous coat is the main factor limited acetylsalicylic acid (ASA) use in patients with atherothrombosis. Up to date the mostly comprehensible way to decrease gastrointestinal complications is taking ASA in the lowest effective dose, which is not higher than 75-81 mg daily. It is necessary if possible to avoid ASK usage in combination with other antiaggregants, anticoagulants, non-steroid and steroid anti-inflammatory drugs. Routine antiulcer therapy is not indicated for patients treated with ASA because there is a lack of clinical research data about efficacy of this approach. In high risk of dangerous gastrointestinal complications H. pylori eradication is recommended in combination with long term preventive therapy with gastric secretion inhibitors. Proton pump inhibitors are more preferred.

Keywords

• ацетилсалициловая кислота
• нестероидные противовоспалительные препараты
• безопасность терапии
• желудочно-кишечные осложнения
• профилактика